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produced by DNA-shuffling of IFN-α, shows
antitumor effect in vitro and in vivo
Meng Li1†, Chunming Rao1†, Dening Pei1, Lan Wang1, Yonghong Li1, Kai Gao1, Minrong Wang2 and Junzhi Wang1*Abstract
Objective: A recombinant antitumor/antiviral protein (Novaferon, Nova) is a new type of interferon, which is
produced by artificial design technology combining DNA-shuffling and High Throughput Screening (HTS).
Methods: The in vitro biological activities, such as anti-tumor activity and antiviral activity of Nova and recombinant
human interferon alpha-2b (rhIFN-α2b) was performed; in vivo anti-tumor activity in nude mice was also tested.
Flow cytometry, histo-pathological analysis including HE staining and immunohistochemistry, and surface plasmon
resonance assay were performed to investigate the underlying mechanisms analysis.
Results: Nova exhibited stronger anti-cancer effects compared to rhIFN-α2b in vitro and in vivo. The antitumor
mechanisms of Nova may be related to S phase arrest, pro-apoptosis, and inhibition of tumor angiogenesis.
Moreover, Nova exhibited a higher binding affinity for IFN receptor 2 (IFNR2) than rhIFN-α2b, which is one of the
possible reasons accounting for its stronger actions against tumor cells compared with rhIFN-α2b.
Conclusion: Nova has strong antitumor activity and could be a potentially effective therapeutic drug for cancer.
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Cancers are becoming a leading cause of morbidity and
mortality worldwide in the coming decades. At present,
the treatment of cancer is the major challenge for the
global medical community [1]. With the advance of mo-
lecular biology and genetic engineering, the development
of anticancer drugs has entered a new stage. Considerable
progress has been made in harnessing biotechnology for
the development of anticancer drugs, such as monoclonal
antibodies, cytokines and interferons.
Interferon (IFN) is one of the most common biotechnol-
ogy drugs which has been widely used in the adjuvant
therapy of tumors [2,3]. Clinical benefits of IFN-α therapy
includes increase in the disease-free survival by ~9 months
and the 5-year survival by 8–9% [4,5]. Interferon possesses
both direct tumor-killing and immunomodulatory effect
[6], IFN-α exerts its effects mainly through the Tyk2/Jak1-* Correspondence: wangjz@nifdc.org.cn
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stated.STAT1/STAT2 pathway to activate transcription from
the IFN-stimulated response element (ISRE) [5]. IFN-α
is currently the most used cytokine in the treatment of
cancer. However, the potential anti-tumour activity of
IFN-α is limited by the activation of tumour resistance
mechanisms [7].
Novaferon (Nova) is a new recombinant IFNα like
anti-tumor/viral protein with significantly higher activities
than IFN-α [8]. Screened from over 10 million artificial
clones of recombinant interferons. Preliminary analysis
suggest it may have more strong bioactivity than normal
IFNα and share the same mechanism on cancer treatment
with interferon in cell cycle arrest, promotion of apoptosis
and inhibition of oncogene expression.
In the current study, we tested Nova’s bioactivities on
tumor cells and virus; secondly, we also probed the
mechanisms of Nova in cancer treatment.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Li et al. Cancer Cell International 2014, 14:8 Page 2 of 9
http://www.cancerci.com/content/14/1/8Materials and methods
Animals and cell lines
Male BALB/c nude mice, 6 weeks old, were purchased
from the National Institutes for Food and Drug Control.
The mice were fed under pathogen-free and humane
conditions. All experiments involving the use of mice were
carried out according to the protocols approved by the
Animal Care and Use Committee of Academy of Military
medical Sciences (Beijing, China). WISH cells (CCL-25),
HepG2 (HB-8065) and Daudi cells (CCL-213) were pur-
chased from ATCC (Manassas, VA, USA). HepG2 cells
were cultured in Eagle's Minimum Essential (EME)
medium (Gibco, NY, USA) supplemented with 10% (v⁄v)
FBS (Invitrogen, CA, USA) in a humidified atmosphere
containing 5% CO2 at 37°C. WISH cells were cultured
in Minimal Essential Medium (MEM) supplemented
with non-essential amino acids and 10% (v⁄v) FBS. Daudi
cells were cultured in RPMI-1640 medium (Gibco, NY,Figure 1 Sequence, molecular weight and purity of Nova. (A) Sequenc
(B) SDS-PAGE separation result (stained with Commassie Brilliant Blue R-25
Nova (reduction), 19.06 KD; Lane 4, Blank; Lane 5: rhIFN-α2b (Non-reducing, 1
formance liquid chromatography analysis result, arrow indicated the NovaUSA) supplemented with 10% (v⁄v) FBS (Invitrogen) in a
humidified atmosphere containing 5% CO2 at 37°C.Reagents
Nova was prepared according to method described previ-
ously [9], in brief, a shuffling library with 12 subtypes of
IFNαs was constructed from human leukocyte cDNAs.
Followed by PCR amplification, DNase I digestion and
anti-tumor/virus activity screening, Novaferon, a human
interferon-like protein was screened. The purity of Nova
was determined by Size Exclusion Chromatography-High-
Performance Liquid Chromatography (SEC-HPLC) assay.
Nova was separated by Shodex Protein KW-803 column
(Showa Denko America, Inc., NY, USA) in PB buffer
(20 mM Na3PO4, 0.5 mM NaCl, 0.02% Tween80, pH7.0).
The purity was calculated by division of the target peak
area and the total peak area.e alignment between IFN-α2b (upper line) and Nova (lower line);
0): Lane 1, marker; Lane 2, rhIFN-α2b (Reduction), 17.51 KD; Lane 3,
00%); Lane 6, Nova (Non-reducing, 100%); (C) Size-exclusion high per-
.
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purchased from Upstate Biotechnology (Temecula,
CA, USA). Antibodies against Bax and Bcl-2 were
purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Antibody against Ki-67 was pur-
chased from Thermo Fisher Scientific (Melbourne,
VIC, Australia). Antibody against α-SMA was purchased
from Abcam (Cambridge, MA, USA). Recombinant hu-
man IFN-α/β R2-Fc chimera, recombinant human IgG1
Fc and goat anti-human IgG Fc was purchased from
R&D Systems (Minneapolis, MN, USA). FITC Annexin V/
PI apoptosis kit was from BD Biosciences (Burlington,
MA, USA).Antiproliferative test in Daudi cells
For the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide; Sigma-Aldrich, Inc., St. Louis,
MO] anti-proliferative assay, Daudi cells (3 × 104 cells/
well) were treated with Nova, rhIFN-α2b and IFN-α
international standard control at an initial concentration
with 4-fold serial dilutions (0 ~ 250 IU/ml) in 10% FBS-
RPMI as previously described [10]. Concentrations of
IFNs that inhibit cell growth by 50% (IC50) were calcu-
lated at 48 h after treatment.Figure 2 The Comparison of Nova and rhIFN-α2b in anti-virus/tumor
rhIFN-α2b determined by WISH-VSV system and Daudi-MTT assay,◇:rhIFN
demonstration of anti-tumor (C) and anti-virus activity (D) of Nova and IFNAnti-viral activity testing by WISH/VSV assay
Vesicular stomatitis virus (VSV) has been reported to
induce apoptosis and the onset of apoptosis may play an
important role in virus-associated diseases [11,12]. We
compared anti- viral activity of Nova and rhIFN-α2b by
virtue of cytopathic effect reduction assay (CPE) that
employed a human amnion cell line(WISH) challenged
with vesicular stomatitis virus (VSV) as described in detail
elsewhere [13], inoculated WISH cells were added in a 96-
well plate at a density of 3 × 105 cells/ml, subsequently
treated with 4-fold serial dilutions (0 ~ 250 IU/ml) of
Nova, rhIFN-α2b and IFN-α international standard con-
trol for 24 h. A total of 1000 pfu VSV was added to in-
fect cells for 12 h. The staining and dissolve procedures
of WISH cell/VSV system were described previously
[14]. Anti-tumor/viral activity of Nova and rhIFN-α2b
was demonstrated as absorption value data of 550 nm
after analyzed by Soft max program.Anti-tumor activity tested by flow cytometry
A total of 1 ml HepG2 cells (105/ml) were added into a
12-well plate, cells were treated with Nova and rhIFN-α2b,
untreated cells served as blank control. Twenty four hours
later, the cells were stained by Propidium Iodide (PI) [15]activity. The anti-tumor (A) and anti-virus (B) activity of Nova and
-α2b, Δ: Nova, Ο: IFN-α international standard control; The column
-α2b, **, P < 0.01, compared with IFN-α2b.
Figure 3 In vivo anti-proliferative activity of Nova. (A) HepG2 tumor volume in each group; (B, left) The relative proliferation rates (R.P.R.) of
Nova, IFN-α2b and fluorouraci. (B, right) The tumor growth inhibition rates (T.I.R.) of Nova, IFN-α2b and fluorouracil. (C) The cell cycle through
propidium iodide (PI) staining, specific S phase cell cycle inhibition was observed in Nova and IFN-α2b groups.
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FACScan flow cytometer (Becton Dickinson, NY, USA).
DNA distributions were analyzed by BD FACSDiva soft-
ware (BD Biosciences, NJ, USA) for the proportions of
cells in S phase of the cell cycle.
In vivo anti-tumor activity in nude mice
Tumors were implanted in BALB/c-nude mice (20–25 g;
n = 32) as previously described [6]. Briefly, 100 μl of
HepG2 cells (1 × 106, viability of 95–97%) were inoculated
into the shoulder of right forelimb. The mice were housed
one per cage with free access to sterile water and standard
laboratory chow diet. When the diameter of the tumors
reached to 4-5 mm, the mice were randomly divided into
four groups (N = 6): Nova group, rhIFN-α2b group, posi-
tive control group (fluorouracil) and negative control
group (PBS). Subcutaneous injection was carried out with
varied doses in different groups: Nova 250 μg/kg, rhIFN-Figure 4 HE staining was observed under the microscope (200×), com
shape changed in the rhIFN- α 2B (B) and nova group (C).α2b 250 μg/kg, fluorouracil 30 mg/kg, PBS 0.1 ml. Nova,
rhIFN-α2b and PBS were administrated once daily for 21
days. Fluorouracil was administrated every other day.
Twenty one days later, anesthetization of sodium pento-
barbital was applied to the mice and then the mice were
sacrificed; RPR (relative proliferation rates) with the tumor
volumes and the TIR (tumor growth inhibition rates) with
the tumor weights were calculated respectively based on
previously similar study [16].
HE and Immunohistochemistry analysis
Excised tumor specimens were fixed in 10% neutral-
buffered formalin. After embeded in paraffin, a series of
5-μm sections were sliced. Sections were de-paraffinized,
and rehydrated. After the sections were de-waxed by xy-
lene and processed by graded ethanol debenzolization.
They were then washed with tap water, differentiated
with hydrochloric acid and ethanol before staining withpared with negative control (A) we observed karyopyknosis and
Figure 5 The immuno histochemical analysis result of caspase 3 in each group. Caspase-3 protein increased in dissected tumor tissues after
mice was treated by IFN-α2b (B) and Nova (C) compared with the negative control (A). D is quantization of the expression of the proteins evaluated in
the different samples with immunohistochemistry.
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quenching endogenous peroxidase activity and blocking
nonspecific binding sites, slides were incubated at 4°C
overnight with 1:100 dilutions of primary antibodies
against Bax, Bcl-2, caspase 3, Ki-67 and α-SMA respect-
ively, followed by 30-min incubation with secondary
antibodies. Slides were then visualized using the DAB
chromogen (Lab Vision Corp., Fremont, CA).Surface Plasmon Resonance (SPR) assay
SPR method is one of effective methods to study direct
macromolecular interactions, compared with indirect
methods, such as ELISA; SPR has the real-time, rapid,
and label-free characteristics. For analysis of Nova and
IFN-a2b affinity for IgG, SPR studies were performed
using a BIAcore T-100 (BIAcore AB, Uppsala, Sweden).
Human IFNR2-Fc was captured on the CM5 chip by an
immobilized anti-human IgG Fc antibody. Nova or IFN-
α2b was added in the solution phase, the binding was
measured under equilibrium conditions. The data were
analyzed by BiacoreT-100 evaluation.Results
Sequence alignment and purity of nova
Nova shares approximately 82% sequence identity to hu-
man IFN-α2b (Figure 1A). The molecular weight of Nova
was about 19 kDa estimated by SDS-PAGE (Figure 1B).
The purity of Nova was at least 99% tested by SEC-HPLC
(Figure 1C).Figure 6 The immuno histochemical analysis result of Bax in each gro
IFN-α2b (B) and Nova (C) compared with the negative control (A). D is qu
samples with immunohistochemistry.Anti-tumor/virus activity of nova
The anti-tumor activity of Nova and IFN-α2b against
Daudi cell lines was 2.74 × 1010 U/mg ± 8.71 × 109 U/mg
(n = 3) and 1.57 × 108 U/mg ± 6.91 × 107 U/mg (n = 3) re-
spectively (Figure 2A). The anti-virus activity of Nova and
IFN-α2b, which was verified by WISH/VSV system, was
1.34 × 109 ± 1.57 × 108 (n = 3) and 1.34 × 108 ± 1.48 × 107
(n = 3) respectively (Figure 2B). Nova shared a high hom-
ology with IFN-α2b, but the anti-tumor and anti-virus
activity of Nova was 174-fold (Figure 2C) and 10-fold
(Figure 2D) greater than IFN-α2b.Enhanced inhibition of nova to Hep-G2 cell proliferation
in nude mice
To explore the anti-proliferative activity of Nova in vivo,
effect of Nova on Hep-G2 cell proliferation in nude mice
was tested. Result showed IFN-α2b and fluorouracil re-
duced the HepG2 tumor volume (Figure 3A), and was
consistent with previous reports [17,18]. The relative pro-
liferation rates (R.P.R.) of Nova, IFN-α2b and fluorouracil
were 17.7%, 75.6% and 48.6%, respectively (Figure 3B,
left). The tumor growth inhibition rates (T.I.R.) of Nova,
IFN-α2b and fluorouracil were 79.5%, 33.8% and 48.9%,
respectively (Figure 3B, right). We also analyzed the cell
cycle through propidium iodide (PI) staining. Specific S
phase cell cycle inhibition was observed in Nova (23%)
and IFN-α2b (18%) treatment groups (Figure 3C). The
results showed that the anti-tumor activity of Nova, a
protein originated from IFN-α, has been enhanced.up. Bax protein increased in tumor tissues after mice was treated by
antization of the expression of the proteins evaluated in the different
Figure 7 The immuno histochemical analysis result of Bcl-2 in each group. Bcl-2 protein decreased in tumor tissues after mice was treated
by IFN-α2b (B) and Nova (C) compared with the negative control (A). D is quantization of the expression of the proteins evaluated in the
different samples with immunohistochemistry.
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our study demonstrates that the apoptosis rate of the
Nova was 13.07%, while in rhIFN-α2b group, the apop-
tosis rate is 9.67%.Novaferon changes the expression of several
apoptosis -related genes
HE staining was observed under the microscope, compared
with negative control, we found that karyopyknosis and
shape change of cells existed in the tumor sample treated
with rhIFN- α 2B and nova (Figure 4).
Caspases, Bax and Bcl-2 proteins were extensively
studied for induction of apoptosis regulation. To explore
the related apoptotic mechanism of Nova, we examined
the protein levels of caspase-3, and Bcl-2 by immunohisto-
chemistry analysis. Result showed caspase-3 protein in-
creased in dissected tumor tissues after mice was treated
by IFN-α2b and Nova compared with the negative control
(Figure 5), the levels of caspase-3 was higher in Nova
group than IFN-α2b group. The expression of Bax pro-
teins (Figure 6) was consistent with caspase-3. On the
other hand, Bcl-2 expression was down-regulated in
IFN-α2b and Nova groups when compared with the
control; the expression of Bcl-2 in Nova groups was less
than IFN-α2b group (Figure 7). Moreover, expression of
proliferation marker Ki-67 (Figure 8) and α-smooth
muscle actin (α-SMA, Figure 9) were down-regulated in
IFN-α2b and Nova groups.Figure 8 Ki-67protein levels ingroup of IFN-α2b (B) and Nova (C) com
analysis. D is quantization of the expression of the proteins evaluated in tBinding of nova and IFN-α2b fused to IFN receptor 2
SPR analysis showed Nova could interact with IFN re-
ceptor 2 (IFNR2) by Biacore T-100 instrument. Binding
curve showed that Nova bind to IFNR2 with higher
affinity (KD =1.23 × 10-11 M than that of rhIFN-α2b
(Kd, 1.59 × 10-9 M) (Figure 10). This data demonstrates
that IFNR2 is a probable receptor of Nova.
Discussion
IFNs were the first cytokines used in treating malignant
tumor, with the approval of recombinant human IFNs,
IFN-α2a and IFN-α2b for the treatment of Hairy Cell
Leukemia and Kaposi’s sarcoma [19], IFNs provide funda-
mental defense strategies against viral infections, tumor
growth and immune disorders. We used rhIFN-α2b as a
positive control to evaluate the therapeutic effect of Nova,
results showed that Nova inhibited proliferation rate of
the HepG2 cell in vitro and in vivo significantly. In our
study, in vivo anti-cancer effect may include many mecha-
nisms, such as immune regulation and cytokine regula-
tion. During their cytotoxic effecting on tumor cells, IFN
could activate monocytes and macrophages, thus produce
free radicals (ROS) and reactive nitrogen intermediates
(RNI) to exert their effect [20]. IFN can also cause de-
creased production of fibroblast growth factor (bFGF),
and reduced transcription of vascular endothelial growth
factor (VEGF) [6,21]. Therefore, in vivo tumor inhib-
ition experiments exerted stronger inhibitory effects
than in vitro tumor cell killing experiments. Moreover,pared with the negative control (A) by immuno histochemical
he different samples with immunohistochemistry.
Figure 9 α-SMA protein levels in groups of IFN-α2b (B) and Nova (C) compared with the negative control (A) by immuno histochemical
analysis. D is quantization of the expression of the proteins evaluated in the different samples with immunohistochemistry.
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in vitro; therefore Nova could demonstrate higher bio-
logical activity than rhIFN-α2b.
Interferon is known to be involved in different phases
of the mitotic cycle, the most common exerted effect is
on the transition from G1 to S phase [22]. Type I and
type II IFNs are capable of inhibiting the expression
transcription factor c-myc, which is essential for activating
cyclin-dependent kinase (CDK), subsequently regulate the
transition from G1 to S phase and induce transcription of
a large genes necessary for S phase [23]. The cell cycleFigure 10 Binding curve showed that Nova (B) bind to IFNR2 with higanalysis showed the percentage of S phase treated with
Nova and rhIFN-α2b was 21.67% and 18.71% respectively,
and the percentage of S phase of the blank control group
was 14.75%. Compared with blank control group, Nova
and IFN-a2b inhibit cell cycle progression by arresting
them in S phase, so that the percentage of cells in S phase
is increased.
Inhibition of DNA synthesis of S phase prevents mi-
totic entry through the action of the S-phase key point
in tumor cells. Thus we speculate that one effect of
Nova on these starved cells was to slow progressionher affinity than IFN-α2b (A).
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tumor.
Apoptosis, also known as programmed cell death, is a
highly conserved eukaryotic cell suicide format [24].
Different from the anti-proliferate effect, apoptosis is
removing aging cells through self-death or injury by the
body and it is the genetic control of programmed cell
death. Pro-apoptotic induction is one of the effective
ways in anti-tumor therapy. Our study suggested that
the ability of inducing apoptosis for Nova may be little
stronger than rhIFN-α2b, but this result need to be further
confirmed.
Cysteine-requiring Aspartate Protease (Caspase) is a
family of proteases, it plays important role in the process
of apoptosis. Caspase-3, belong to the caspase family
CED-3 subfamily [25], is a key enzyme regulating apop-
totic process. In addition, caspase-3 also plays a key role
in chromatin condensation, DNA fragmentation during
apoptosis. Caspase-3 pro-enzyme stays in the cytoplasm
of normal cells, at the early stages of apoptosis, it is acti-
vated and induces apoptosis eventually [26]. Up-regulated
Caspase-3 expression demonstrates that nova exerts its’
effect through inducing apoptosis in tumor cells [27].
Bax, also known as Bcl-2 associated protein X, is another
member of the Bcl-2 family [28]. It is a pro-apoptotic pro-
tein in the mitochondria-dependent apoptosis pathway.
In healthy mammalian cells, Bax is inactive in the cyto-
plasm. Once triggered by signals, Bax is transferred to
the mitochondrial outer membrane, and begin to induce
mitochondrial release of apoptosis gene factor, trigger-
ing the apoptotic response [29]. Interferon could up
regulate Bak and Bax in response to apoptosis [30],
which is consistent with our data. Also, we observed the
down-regulation of anti-apoptotic proteins Bcl-2 in
HepG2 tumor cells by Nova.
Ki-67, which is encoded by MKI67, is a cell proliferation-
related nuclear protein used for diagnosing tumor cell
proliferation [31]. Ki-67 expresses at the G1, S, G2 and
mitosis phase, and is related with ribosomal RNA tran-
scription [32]. Ki-67 staining is commonly used for diag-
nosis of malignant tumors. In our study; we observed that
Ki67 in Nova treatment group is reduced than that in
rhIFN-α2b group. The α-SAM was found in tumor vascu-
lar smooth muscle cells, is a common cancer-associated fi-
broblasts which has tumor protective role, in consistent
with Ki-67, our study demonstrate Nova could down regu-
late expression of α-SAM and has better effect of anti-
angiogenesis in tumor blood vessels than rhIFN-α2b.
Moreover, DNA contamination, endotoxin content, re-
sidual antibiotic activity and residual bacteria protein con-
tent of Nova is all below the limits of detection (data not
shown). In a conclusion, Nova could be a potential power-
ful anti-tumor/virus drug; however, this also requires fur-
ther clinical trials to verify.Competing interests
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